Coronary Stenting With the GenousTM Bio-Engineered R StentTM in Elderly Patients - 12-Month Outcomes From the e-HEALING Registry -

Abstract

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp s a consequence of the increasing age of populations worldwide, the elderly represent an important subgroup of patients undergoing percutaneous coronary intervention (PCI). These elderly constitute a high-risk group for complications after PCI. 1 Yet despite higher mortality, vascular and bleeding complications; restenosis rates after baremetal stenting (BMS) have been reported to be comparable to those of younger patients. 2 Compared with BMS, drug-eluting stents (DES) have been shown to reduce the incidence of in-stent-restenosis by inhibiting or delaying neo-endothelialization. 3-5 In 2 large registries, the use of DES in the elderly was associated with lower repeat revascularization rates when compared with BMS placement. 6,7 However, treating the elderly with DES is potentially hampered by an increased incidence of comorbidities, the increased need for (non-)cardiovascular interventions with the accompanying temporary discontinuation of antiplatelet therapy, and low therapeutic compliance or drug interactions because of multiple medications. Thus the elderly patients are at an increased risk of (temporary) discontinuation of clopidogrel, which is associated with a higher risk of developing stent thrombosis (ST). 8, 9 The Genous TM endothelial progenitor cell (EPC) capturing stent TM has been shown to be associated with a low incidence of repeat revascularization and ST at 12 months with the recommended month of dual antiplatelet therapy (DAPT Background: We evaluated the Genous TM Bio-engineered R stent TM in elderly patients undergoing non-urgent percutaneous coronary intervention. The elderly have an increased risk of (temporary) discontinuation of clopidogrel, which is associated with a higher risk of developing stent thrombosis (ST).

9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Liberté stents

“…Tables 5 and 6 summarizes the main data from the literature on Genous stents and lists the main outcomes [ 8 , 11 – 15 , 19 – 30 ].…”

“…The Genous stent device has been described elsewhere [ 19 ]. In cases with multiple lesions, the infarct-related artery was determined based on the coronary morphology, the presence of possible vessel thrombus, and the location of the ECG changes.…”

In situ Endothelialization: Bioengineering Considerations to Translation

“…In addition to above studies, several other studies were conducted using the same registry to evaluate outcomes on different patient subpopulation (e.g., diabetic and elderly patients, DAPT duration and regional location) …”

Biomaterials in Cardiovascular Research: Applications and Clinical Implications

“…To add further, Genous stent used in a population of elderly patients resulted in a significantly higher target vessel failure rates compared with younger patients. Moreover, target lesion revascularization rates were higher with increasing age and there was no difference in stent thrombosis [94]. Another worthy research to mention is the use of exponential enrichment technology in which DNA-aptamers with a high affinity to EPCs were identified.…”